Skip to main content

Table 1 Patient characteristics

From: Circulating miR-21 as a prognostic biomarker in HCC treated by CT-guided high-dose rate brachytherapy

Baseline features

Overall

Responders (n = 12)

Non-resp. (n = 12)

p-value

Number/Median

Range (IQR) %

Number/Median

Range (IQR)/%

Number/Median

Range (IQR)/%

Sex

       

Female

4

16.7

2

16.7

2

16.7

1

Male

20

83.3

10

83.3

10

83.3

1

Age (years)

69

50–84 (21)

68.5

58–87 (21.5)

68.5

44–86 (32.5)

0.80

Etiology

       

Alcohol

9

37.5

5

41.7

4

33.3

1

NASH

3

12.5

1

8.3

2

16.7

1

Hepatitis B

4

16.7

1

8.3

3

25

0.59

Hepatitis C

6

25

4

33.3

2

16.7

0.64

Unknown

6

25

3

25

3

25

1

Multiple

4

16.7

2

16.7

2

16.7

 

Child–Pugh A

19

79.2

10

83.3

9

75

1

Child–Pugh B

5

20.8

2

16.7

3

25

 

AFP [ng/ml]

5.25

1.6–35,754 (7)

5.25

1.6–21.5 (4.65)

5.45

2.0–35,754 (32.15)

0.77

AFP ≥ 20 ng/ml

4

16.7

1

8.3

3

25

0.59

Portal vein thrombosis

0

0

0

0

0

0

1

Sum lesion diameter [cm]

3

1.1–10.9 (3.23)

2.9

1.7–10.3 (1.08)

3.5

1.1–10.9 (4.75)

0.49

Max. tumor diameter [cm]

2.5

1.1–10.3 (1.63)

2.7

1.7–10.3 (0.8)

2.3

1.1–10.0 (5.67)

0.31

Tumor number treated

       

1

16

66.7

10

83.3

6

50

0.19

2

8

33.3

2

16.7

6

50

  1. NASH, non alcoholic steatohepatitis; AFP, alpha-fetoprotein